GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sophiris Bio Inc (OTCPK:SPHS) » Definitions » Cyclically Adjusted Price-to-FCF

Sophiris Bio (Sophiris Bio) Cyclically Adjusted Price-to-FCF : (As of May. 06, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Sophiris Bio Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Sophiris Bio Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Sophiris Bio's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sophiris Bio Cyclically Adjusted Price-to-FCF Chart

Sophiris Bio Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sophiris Bio Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sophiris Bio's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Sophiris Bio's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sophiris Bio's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sophiris Bio's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Sophiris Bio's Cyclically Adjusted Price-to-FCF falls into.



Sophiris Bio Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Sophiris Bio's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2019 is calculated as:

For example, Sophiris Bio's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2019 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2019 (Change)*Current CPI (Sep. 2019)
=-0.084/108.3294*108.3294
=-0.084

Current CPI (Sep. 2019) = 108.3294.

Sophiris Bio Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
200912 -1.433 91.111 -1.704
201003 -0.817 91.821 -0.964
201006 0.767 91.962 0.904
201009 -0.314 92.162 -0.369
201012 -0.969 92.474 -1.135
201103 -0.523 94.283 -0.601
201106 -1.872 95.235 -2.129
201109 -0.972 95.727 -1.100
201112 -2.002 95.213 -2.278
201203 -1.556 96.783 -1.742
201206 -1.367 96.819 -1.530
201209 -2.043 97.633 -2.267
201212 -1.212 96.871 -1.355
201303 -1.012 98.209 -1.116
201306 0.333 98.518 0.366
201309 -0.703 98.790 -0.771
201312 -0.271 98.326 -0.299
201403 -0.380 99.695 -0.413
201406 -0.441 100.560 -0.475
201409 -0.379 100.428 -0.409
201412 -0.382 99.070 -0.418
201503 -0.335 99.621 -0.364
201506 -0.227 100.684 -0.244
201509 -0.182 100.392 -0.196
201512 -0.108 99.792 -0.117
201603 -0.147 100.470 -0.158
201606 -0.114 101.688 -0.121
201609 -0.138 101.861 -0.147
201612 -0.070 101.863 -0.074
201703 -0.108 102.862 -0.114
201706 -0.053 103.349 -0.056
201709 -0.081 104.136 -0.084
201712 -0.088 104.011 -0.092
201803 -0.127 105.290 -0.131
201806 -0.118 106.317 -0.120
201809 -0.133 106.507 -0.135
201812 -0.070 105.998 -0.072
201903 -0.113 107.251 -0.114
201906 -0.077 108.070 -0.077
201909 -0.084 108.329 -0.084

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sophiris Bio  (OTCPK:SPHS) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Sophiris Bio Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Sophiris Bio's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Sophiris Bio (Sophiris Bio) Business Description

Industry
Traded in Other Exchanges
N/A
Address
1258 Prospect Street, La Jolla, CA, USA, 92037
Sophiris Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of products for the treatment of urological diseases. The company's product portfolio includes topsalysin (PRX302), for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. Topsalysin is a genetically modified recombinant protein which is selectively activated by enzymatically active prostate-specific antigen (PSA), which is only present in the prostate, leading to localized cell death and tissue disruption without damage to neighboring tissue and nerves. Geographically all the operations of the company are functioned in the United States.
Executives
Randall E Woods director, officer: President & Chief Exec Officer C/O ARENA PHARMACEUTICALS, INC. 6166 NANCY RIDGE DRIVE SAN DIEGO CA 92121
Lars Ekman director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
James L Heppell director
Gerald T Proehl director
John Geltosky director 685 ROUTE 202/206, BRIDGEWATER NJ 08807
Joseph L Turner director 10505 ROSELLE STREET, SAN DIEGO CA 92121
Joseph Lewis 10 percent owner PO BOX N7776, LYFORD BAHAMAS
Boxer Asset Management Inc. 10 percent owner CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Boxer Capital, Llc 10 percent owner 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Mva Investors, Llc 10 percent owner 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
William R Rohn director PO BOX 676367, RANCHO SANTA FE CA 92067